Total Omega-6

You may have heard that the fats in vegetable oils, nuts, and seeds inflame your arteries. Human studies mostly tell a different story. In the largest pooled studies, people with more linoleic acid, the main fat in this family, were less likely to die from cardiovascular disease, have ischemic strokes, or develop type 2 diabetes.

Total omega-6 reports the combined share of measured fatty acids that comes from this family. It mostly reflects what you've eaten over the past weeks to months, but it is an emerging marker without standardized cutpoints. Most outcome research measured linoleic acid in blood or tissue rather than the full total, so read this result as fatty-acid context, not as a diagnosis.

What the Number Represents

Omega-6 fats are a family of polyunsaturated fats that share one feature of their chemical structure. The main member is linoleic acid. Your body can't make it, so the amount you carry follows your diet. From linoleic acid your body builds a few longer fats, and the best known of these is arachidonic acid.

Total omega-6 adds these fats together, and labs usually report the result as a percentage of all the fatty acids measured. Labs measure fatty acids in different sample types and fractions, including plasma, red blood cell membranes, and specific fat fractions. Those numbers aren't interchangeable, and a percentage can't be compared with an absolute concentration.

Arachidonic acid is also the raw material for prostaglandins and leukotrienes. These are signaling molecules that help switch inflammation on, which is where omega-6 gets its reputation. The total tells you how much raw material is present in the measured pool. How much inflammation is happening is a separate question, and you need other tests to answer it.

Heart Disease and Stroke

Most of the outcome research measured linoleic acid in blood or tissue, and didn't use the full omega-6 total. Linoleic acid makes up most of the total, so these studies are the closest evidence for your number, but they measured one part of it.

The largest analysis pooled 30 cohort studies covering 68,659 people and 15,198 cardiovascular events. When people near the top of the linoleic acid range were compared with people near the bottom, cardiovascular deaths were about 22% lower, strokes caused by blocked arteries were about 12% lower, and total cardiovascular disease was about 7% lower. Arachidonic acid wasn't linked to higher risk, and at the extremes it went with somewhat lower total cardiovascular risk.

Older adults showed the same pattern. In 2,792 participants in the Cardiovascular Health Study, higher circulating linoleic acid went with lower total mortality and a much lower risk of dying from coronary heart disease not caused by rhythm problems. Age, sex, race, and omega-3 status made little difference to that link.

Randomized trials are less convincing. When a Cochrane review pooled trials that asked people to eat more omega-6 fat, it found little or no difference in deaths or cardiovascular events. Heart attacks trended lower, and total cholesterol fell by about 13 mg/dL. The review rated the evidence on events as low quality and the cholesterol finding as high quality.

What this means for you: a low result matches the pattern the large cohorts tie to higher cardiovascular risk, so it's worth looking at where the fat in your diet comes from and checking your other heart markers. A high result on its own isn't the warning sign it's often made out to be.

Type 2 Diabetes

A pooled analysis of 20 prospective studies followed 39,740 adults who didn't have diabetes at the start. Those with more linoleic acid in their blood or tissue were less likely to develop type 2 diabetes. Arachidonic acid had no significant link either way.

The association held across age, BMI, sex, race, aspirin use, and omega-3 level. It also held regardless of variation in the genes that convert these fats into longer forms. Trials that raised omega-6 intake found little or no effect on preventing or treating type 2 diabetes, though. So read your result as a marker of an eating pattern linked to lower risk. The trials don't show that adding more of these fats lowers diabetes risk by itself.

Longevity and Cancer

A 2025 meta-analysis of 150 cohorts found that higher dietary or circulating omega-6 went with lower all-cause mortality, and that higher circulating levels went with lower cardiovascular mortality. In UK Biobank, higher plasma omega-6 percentage tracked with lower all-cause, cancer, and cardiovascular mortality. A separate review of meta-analyses rated the evidence tying omega-6 intake to lower cardiovascular, cancer, and all-cause mortality as moderate quality. The 150-cohort analysis found these links mainly in the general population and less clearly in people who already had health conditions.

Cancer results depend on the cancer. Circulating omega-6 tracked with lower overall cancer incidence in pooled analyses, while dietary-intake studies reported higher ovarian and endometrial cancer risk. For colorectal cancer, total omega-6 showed no clear association, while higher dietary linoleic acid was linked to higher colorectal and rectal cancer risk. Tissue levels of linoleic acid showed no significant link. Randomized trials suggest that raising total polyunsaturated fat may slightly increase overall cancer risk, offset by small cardiovascular benefits.

What this means for you: if colorectal, ovarian, or endometrial cancer runs in your family, a high result isn't cause for alarm. It is a reason not to push the number up with large amounts of added oil when the cardiovascular evidence doesn't support chasing a very high number.

Inflammation

The usual theory is that arachidonic acid feeds inflammatory signals, so more omega-6 means more inflammation. Human data mostly don't support it. In healthy adults, eating more linoleic or arachidonic acid didn't raise most common inflammatory markers.

In a national US health survey of 43,155 people, higher omega-6 intake went with lower levels of several immune and inflammatory markers. Among 2,777 participants in the Framingham Offspring Study, red blood cell linoleic and arachidonic acid were weakly linked to lower levels of multiple inflammatory markers. Long-term randomized trials had little omega-6 data on inflammation, and where data existed they showed little or no effect.

Findings That Point the Other Way

A few studies run against the main pattern. Mendelian randomization studies treat inherited gene variants that raise or lower fatty acid levels as a natural experiment. One linked genetically higher omega-6 and linoleic acid to higher coronary heart disease risk, and another flagged arachidonic acid for heart attack, stroke, fasting blood sugar, and LDL.

A 2025 study of 5,070 US adults found a U-shaped relationship between serum omega-6 and cardiovascular death, with higher risk at both the low and high ends. In the Ludwigshafen Risk and Cardiovascular Health Study of 3,259 people, red blood cell omega-6 fats pointed in opposite directions. Some of the minor ones went with lower mortality and others with higher. Among about 96,000 Adventist Health Study 2 participants, a higher dietary omega-6 to omega-3 ratio went with more fatal strokes.

These findings fit together if you treat total omega-6 as a summary of several fats. Most of the total is linoleic acid, and the largest pooled studies consistently tie more linoleic acid to less cardiovascular disease, diabetes, and death. The gene-based studies have a known weakness: the same variants can affect other traits that also drive risk. They don't outweigh the larger prospective record. What they and the U-shaped finding do suggest is that very high levels, or a total weighted toward arachidonic acid and the minor longer omega-6 fats, are worth checking at the level of the individual fats.

Why the Omega-3 Side Matters

Total omega-6 is a share of all your fatty acids, so it moves partly with how much omega-3 you carry. In UK Biobank, a higher plasma omega-6 to omega-3 ratio went with higher all-cause, cancer, and cardiovascular mortality, even though omega-6 and omega-3 were each linked to lower mortality when looked at separately. The risk seemed to track with having too little omega-3 compared with omega-6, which is different from omega-6 being harmful on its own.

The ratio pattern also turns up in particular groups. In middle-aged and older Japanese adults with diabetes, a higher dietary omega-6 to omega-3 ratio was linked to chronic kidney disease, and no such link appeared in those without diabetes. The ratio has limits as well. Lumping different omega-6 fats together can hide differences between them, and eating more linoleic acid doesn't usually raise arachidonic acid in plasma or fat tissue.

What this means for you: read your total omega-6 next to your omega-3 index. The same omega-6 total means something different when your omega-3 is low than when you have plenty of it.

When Results Can Be Misleading

• Which sample or fraction was measured: plasma results vary more from draw to draw, while red blood cell results change slowly and track tissue levels better. Results from different sample types or blood fractions, or reported as percentages versus concentrations, can't be compared.
• High-dose omega-3: because the result is a share of the total, a large omega-3 intake takes up room in the measured pool and lowers the omega-6 percentage within weeks. A drop after starting fish oil doesn't mean you're eating less omega-6.
• Fasting and timing: follow the lab's collection instructions, and repeat the same routine each time. If one result was fasting and another wasn't, the comparison may be noisier.
• Metabolic state: fatty acid profiles and omega-6 to omega-3 measures can track with body fat, insulin resistance, liver markers, and kidney-albumin markers in metabolic disease studies. A shift can reflect broader metabolic change rather than diet alone.

Tracking Your Trend

A single reading is a snapshot, and plasma values move around even when your diet doesn't. Repeated results tell you more: whether your level sits consistently low or high, whether a change in the fats you eat moved it, and how it shifts compared with your omega-3 level.

Get a baseline. If you change your diet or start or stop high-dose omega-3, retest in 3 to 4 months. Red blood cell results need that long to turn over; plasma can move faster, but a longer interval makes the comparison less noisy. After that, test at least once a year. Use the same lab, the same sample type, and the same collection routine each time, or the comparison won't mean much.

What to Do With an Unexpected Result

Read your result as one part of a pattern. This marker isn't a diagnostic test for any disease. In a study of carotid artery plaque, individual fatty acid markers varied too widely between people to work well on their own. A combined fatty acid model did better, catching 84.0% of cases and correctly clearing 72.9% of people without plaque.

• Low omega-6 and low omega-3: your diet is probably light on polyunsaturated fat overall. This is the pattern the large cohorts tie to more cardiovascular disease and diabetes, so check your ApoB, lipid panel, and average blood sugar (HbA1c) alongside it.
• Low omega-6 and high omega-3: this usually reflects heavy fish oil use and isn't worrying by itself. Confirm it with your omega-3 index.
• High omega-6 and low omega-3: this is the high-ratio pattern linked to higher mortality in UK Biobank. Order the omega-3 index and the arachidonic acid to EPA ratio, and work on the omega-3 side first.
• A total weighted toward arachidonic acid: look at the individual fats, since the conflicting signals in the research cluster around arachidonic acid and the minor longer omega-6 fats.

If your fatty acid pattern comes with high ApoB, rising blood sugar, insulin resistance, or abnormal liver enzymes, the fat balance probably reflects a broader metabolic problem, and those markers should guide what you do next. A lipidologist can help when cardiovascular markers stay off despite changes to your diet. A registered dietitian can help you adjust which fats you eat without guesswork.